WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis. Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab ...
(RTTNews) - enGene Holdings Inc. (ENGN) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead drug candidate ...
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with ...
A number of researchers from Stanford University Medical School, Columbia University, and Beaumont Hospitals in the United ...
IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results